Abstract
A number of hepatic and extra-hepatic autoimmune disorders may complicate a percentage of patients with hepatitis C virus (HCV) infection that is both hepatotropic and lymphotropic agent; the resulting clinical phenotypes can be grouped into the so-called HCV syndrome. This latter includes various rheumatic disorders that are frequently characterized by clinical or serological overlap; thus, a correct patients’ classification is necessary prior to decide the therapy.
The management of these conditions is particularly difficult, given the coexistence of viral infection and immunological alterations. In this scenario, cryoglobulinemic vasculitis represents the prototype of HCV-related rheumatic disorders that can be treated at different levels by means of etiological (antivirals) and/or pathogenetic and/or symptomatic treatments (rituximab, cyclophosphamide, steroids, plasmapheresis, etc). In clinical practice, the therapeutic strategy should take into account the specific symptoms combination and the severity/activity of the disease, according to each patient’s conditions. This review focuses on the clinico-diagnostic assessments and therapeutical approaches of some rheumatic disorders complicating HCV infection, mainly arthritis, sicca syndrome, and osteosclerosis; while, cryoglobulinemic vasculitis is comprehensively examined in another article of the present issue.
Keywords: Hepatitis C virus, HCV, mixed cryoglobulinemia, vasculitis, arthritis, Sjögren’s syndrome, ostesclerosis, lymphoma, antiviral, rituximab.
Current Drug Targets
Title:HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Volume: 18 Issue: 7
Author(s): Marco Sebastiani, Dilia Giuggioli, Michele Colaci, Poupak Fallahi, Laura Gragnani, Alessandro Antonelli, Anna Linda Zignego and Clodoveo Ferri*
Affiliation:
- Rheumatology Unit, Department of Internal Medicine, University of Modena and Reggio E., Policlinico di Modena, Via del Pozzo, 71, 41100 Modena,Italy
Keywords: Hepatitis C virus, HCV, mixed cryoglobulinemia, vasculitis, arthritis, Sjögren’s syndrome, ostesclerosis, lymphoma, antiviral, rituximab.
Abstract: A number of hepatic and extra-hepatic autoimmune disorders may complicate a percentage of patients with hepatitis C virus (HCV) infection that is both hepatotropic and lymphotropic agent; the resulting clinical phenotypes can be grouped into the so-called HCV syndrome. This latter includes various rheumatic disorders that are frequently characterized by clinical or serological overlap; thus, a correct patients’ classification is necessary prior to decide the therapy.
The management of these conditions is particularly difficult, given the coexistence of viral infection and immunological alterations. In this scenario, cryoglobulinemic vasculitis represents the prototype of HCV-related rheumatic disorders that can be treated at different levels by means of etiological (antivirals) and/or pathogenetic and/or symptomatic treatments (rituximab, cyclophosphamide, steroids, plasmapheresis, etc). In clinical practice, the therapeutic strategy should take into account the specific symptoms combination and the severity/activity of the disease, according to each patient’s conditions. This review focuses on the clinico-diagnostic assessments and therapeutical approaches of some rheumatic disorders complicating HCV infection, mainly arthritis, sicca syndrome, and osteosclerosis; while, cryoglobulinemic vasculitis is comprehensively examined in another article of the present issue.
Export Options
About this article
Cite this article as:
Sebastiani Marco, Giuggioli Dilia, Colaci Michele, Fallahi Poupak, Gragnani Laura, Antonelli Alessandro, Zignego Linda Anna and Ferri Clodoveo*, HCV-Related Rheumatic Manifestations and Therapeutic Strategies, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150907103622
DOI https://dx.doi.org/10.2174/1389450116666150907103622 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxic Shock Syndrome and Persistent Immune Activation in an HIVPositive Patient
Current HIV Research Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) Association of Common Variants in the IL-33/ST2 Axis with Ischemic Stroke
Current Neurovascular Research New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Potassium Channels and Uterine Vascular Adaptation to Pregnancy and Chronic Hypoxia
Current Vascular Pharmacology Imaging Markers of Neurologic Damage in COVID-19: A Systematic Review
Current Medicinal Chemistry The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Role of Invariant Natural Killer T (iNKT) Cells in Systemic Lupus Erythematosus
Current Medicinal Chemistry Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Antineutrophil Cytoplasmic Antibody in Lupus Nephritis: Correlation with Clinicopathological Characteristics and Disease Activity
Current Rheumatology Reviews Editorial [Hot Topic: New Therapeutic Options in Central Nervous System Involvement of Rheumatologic Diseases (Executive Editor: Ali Gur)]
Current Pharmaceutical Design Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Multiple Roles of the Extracellular Matrix in Inflammation
Current Pharmaceutical Design Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued)